BMT CTN Protocol 1902 / MM CAR-T to Upgrade Response

BMT CTN 1902 / MM CAR-T to Upgrade Response - Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide

             Co-Chair: Alfred Garfall, MD alfred.garfall@pennmedicine.upenn.org

             Co-Chair: Sergio Giralt, MD giralts@mskcc.org

             Protocol Officer: Marcelo Pasquini, MD mpasquini@mcw.edu

             BMT CTN DCC Coordinator: Megan Scott mscott@emmes.com